Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have been given an average recommendation of “Buy” by the seventeen research firms that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $71.77.
Several research analysts have recently issued reports on the company. Guggenheim assumed coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 price objective for the company. Mizuho restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. BidaskClub upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Finally, Cantor Fitzgerald set a $77.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 18th.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up $0.55 during midday trading on Friday, reaching $53.10. The company’s stock had a trading volume of 269,000 shares, compared to its average volume of 380,116. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. The firm has a market capitalization of $1,920.00, a P/E ratio of -15.64 and a beta of 0.87. Aerie Pharmaceuticals has a fifty-two week low of $38.14 and a fifty-two week high of $66.60.
Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its position in Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares in the last quarter. Quantbot Technologies LP raised its position in Aerie Pharmaceuticals by 792.5% during the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after acquiring an additional 2,647 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in Aerie Pharmaceuticals during the fourth quarter valued at approximately $176,000. Amalgamated Bank purchased a new position in Aerie Pharmaceuticals during the second quarter valued at approximately $204,000. Finally, Great West Life Assurance Co. Can raised its position in Aerie Pharmaceuticals by 65.0% during the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after acquiring an additional 1,639 shares in the last quarter. Institutional investors own 97.81% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Aerie Pharmaceuticals Inc (AERI) Receives $71.77 Consensus PT from Analysts” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/13/aerie-pharmaceuticals-inc-aeri-receives-71-77-consensus-pt-from-analysts.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.